Next 10 |
home / stock / eyen / eyen articles
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern ...
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic pharmaceutical technology company, toda...
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quar...
The Dow Jones closed lower by around 80 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around t...
William Blair initiated coverage on Eyenovia Inc (NASDAQ: EYEN), a biopharma company focused on developing therapies based on its Op...
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares jumped 232% to $3.36 in pre-market trading. United Therapeutics Corporation (N...
In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions Presen...
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company commercializing Mydcombi™ for...
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic technology company commercializing Mydc...
News, Short Squeeze, Breakout and More Instantly...
Eyenovia Inc. Company Name:
EYEN Stock Symbol:
NASDAQ Market:
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalm...
Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025 Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobe...
Company to demonstrate Mydcombi™ and Avenova ® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms ...